export interface ArticleSection {
  heading: string;
  content: string;
  list?: string[];
}

export interface ArticleFAQ {
  question: string;
  answer: string;
}

export interface Article {
  slug: string;
  title: string;
  metaTitle: string;
  metaDescription: string;
  keywords: string[];
  publishedDate: string;
  modifiedDate: string;
  category: string;
  readTime: number; // minutes
  excerpt: string;
  sections: ArticleSection[];
  faqs: ArticleFAQ[];
  relatedProducts: string[];
  relatedSlugs: string[];
}

export const articles: Article[] = [
  {
    slug: "bpc-157-research-overview",
    title: "BPC-157 Research Overview: What Scientists Are Studying",
    metaTitle: "BPC-157 Research Overview: What Scientists Are Studying | Vertex Research Labs",
    metaDescription:
      "A research-focused overview of BPC-157 (Body Protection Compound 157), covering its amino acid structure, mechanism studies, preclinical research history, and published literature. Lab use only.",
    keywords: [
      "BPC-157 research",
      "BPC-157 studies",
      "BPC-157 mechanism",
      "BPC-157 peptide science",
      "body protection compound 157 research",
      "BPC-157 preclinical",
      "BPC-157 published research",
      "BPC-157 amino acid sequence",
    ],
    publishedDate: "2025-01-15",
    modifiedDate: "2025-04-01",
    category: "Research Overview",
    readTime: 7,
    excerpt:
      "BPC-157 is a synthetic pentadecapeptide that has attracted significant attention in preclinical research. This overview summarizes its structural properties, receptor interactions studied in the literature, and the published research record.",
    sections: [
      {
        heading: "What Is BPC-157?",
        content:
          "BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protective protein sequence found in human gastric juice. Its full sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, and it has a molecular weight of approximately 1419.5 Da. BPC-157 does not occur naturally in isolation; it is a partial sequence isolated from the parent gastric protein BPC and is available only as a synthetic research reference material.",
      },
      {
        heading: "Structural Properties",
        content:
          "As a pentadecapeptide, BPC-157 contains multiple proline residues which confer conformational rigidity, contributing to its relative stability compared to many other peptide sequences. Its chemical formula is C₆₂H₉₈N₁₆O₂₂. In laboratory settings it is supplied as a lyophilized (freeze-dried) powder and requires reconstitution with an appropriate sterile diluent before use in in vitro or in vivo research protocols.",
        list: [
          "Length: 15 amino acids (pentadecapeptide)",
          "Molecular weight: ~1419.5 Da",
          "Formula: C₆₂H₉₈N₁₆O₂₂",
          "Standard supply form: lyophilized powder",
          "Typical research purity standard: ≥99% by HPLC",
        ],
      },
      {
        heading: "Preclinical Research History",
        content:
          "The majority of published BPC-157 research originates from the laboratory of Professor Predrag Sikiric at the University of Zagreb. Studies appearing in journals including Current Pharmaceutical Design, Journal of Applied Physiology, and Journal of Physiology-Paris have examined BPC-157's interactions with nitric oxide (NO) signaling pathways, growth factor receptor expression, and cytoskeletal dynamics in rodent models. These are preclinical animal studies and do not constitute evidence of safety or efficacy in humans.",
      },
      {
        heading: "Key Research Areas in the Published Literature",
        content:
          "Published preclinical investigations have explored several areas of BPC-157 biology. It is important to note that all cited research represents animal or cell-culture findings only and has not been validated in human clinical trials.",
        list: [
          "Nitric oxide (NO) pathway interactions in rodent models",
          "VEGFR2 and FAK receptor expression in cell culture",
          "Tendon-to-bone junction healing models in rats",
          "Gut motility and gastric mucosal models",
          "Cytoskeletal (actin/tubulin) effects in vitro",
        ],
      },
      {
        heading: "Research Purity Standards",
        content:
          "For reproducible laboratory research, BPC-157 reference material should meet a minimum purity threshold of ≥99% as verified by High-Performance Liquid Chromatography (HPLC). Each batch should be accompanied by a Certificate of Analysis (COA) confirming purity, molecular identity (typically via mass spectrometry), and batch traceability. At Vertex Research Labs, every BPC-157 shipment includes independent third-party COA documentation.",
      },
      {
        heading: "Important Research Disclaimer",
        content:
          "All BPC-157 reference materials supplied by Vertex Research Labs are intended strictly for in vitro laboratory research and analytical applications. This material is not approved by the FDA or any regulatory authority for human or veterinary use. Nothing in this article constitutes medical advice, and BPC-157 should not be used outside of an authorized research setting.",
      },
    ],
    faqs: [
      {
        question: "What does BPC stand for in BPC-157?",
        answer:
          "BPC stands for Body Protection Compound. BPC-157 is a 15-amino-acid partial sequence derived from the larger BPC protein found in human gastric juice.",
      },
      {
        question: "Is there published clinical trial data on BPC-157?",
        answer:
          "As of 2025, the vast majority of BPC-157 research is preclinical — conducted in cell culture or rodent models. Limited early-phase human studies have been reported but no large-scale randomized controlled trials have been completed or published.",
      },
      {
        question: "What purity should research-grade BPC-157 be?",
        answer:
          "The standard benchmark for research-grade BPC-157 is ≥99% purity as verified by HPLC, accompanied by a Certificate of Analysis confirming identity and batch documentation.",
      },
      {
        question: "Where can I find published BPC-157 research?",
        answer:
          "PubMed is the primary database for peer-reviewed BPC-157 publications. Searching 'BPC-157' or 'body protection compound 157' returns the majority of indexed studies, predominantly from the Sikiric research group at the University of Zagreb.",
      },
    ],
    relatedProducts: ["bpc-157", "tb-500", "wolverine-blend"],
    relatedSlugs: [
      "tb-500-thymosin-beta-4-research",
      "research-grade-peptide-purity-standards",
      "how-to-read-peptide-coa",
    ],
  },

  {
    slug: "ghk-cu-copper-peptide-guide",
    title: "GHK-Cu Copper Peptide: Laboratory Reference Guide",
    metaTitle: "GHK-Cu Copper Peptide: Laboratory Reference Guide | Vertex Research Labs",
    metaDescription:
      "Comprehensive laboratory reference guide for GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper). Covers structure, copper-binding chemistry, published research, and purity standards for lab use.",
    keywords: [
      "GHK-Cu research",
      "GHK-Cu copper peptide guide",
      "GHK-Cu mechanism",
      "glycyl histidyl lysine copper",
      "copper peptide research",
      "GHK-Cu gene expression research",
      "GHK-Cu antioxidant research",
      "copper binding tripeptide",
    ],
    publishedDate: "2025-01-22",
    modifiedDate: "2025-04-01",
    category: "Research Overview",
    readTime: 6,
    excerpt:
      "GHK-Cu is a naturally occurring copper-binding tripeptide studied extensively in cell biology research. This guide covers its chemistry, copper coordination, published research landscape, and specifications for laboratory use.",
    sections: [
      {
        heading: "What Is GHK-Cu?",
        content:
          "GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper) is a tripeptide-copper(II) complex that occurs naturally in human plasma, saliva, and urine. It was first isolated by Loren Pickart in 1973 and has since become one of the most studied naturally occurring peptides in biochemistry research. The free tripeptide (GHK) has high affinity for copper(II) ions, and the resulting complex (GHK-Cu) is the primary research form.",
      },
      {
        heading: "Copper Coordination Chemistry",
        content:
          "The copper(II) ion in GHK-Cu is coordinated by three nitrogen atoms from the peptide backbone: the N-terminal amine of glycine, the peptide nitrogen between glycine and histidine, and the imidazole nitrogen of histidine. This square-planar coordination geometry is characteristic of type-II copper complexes and is central to GHK-Cu's documented interactions with biological systems in research settings.",
        list: [
          "Metal: Copper(II) (Cu²⁺)",
          "Coordination: Square-planar, 3N donor atoms",
          "Affinity constant for Cu²⁺: ~10¹⁷ M⁻¹ (extremely high)",
          "Molecular weight (GHK): ~340.4 Da",
          "Molecular weight (GHK-Cu): ~403.9 Da",
        ],
      },
      {
        heading: "Published Research Landscape",
        content:
          "GHK-Cu is among the most published naturally occurring peptides in biochemistry. Research by Pickart and colleagues, appearing in International Journal of Molecular Sciences (2015) and Oxidative Medicine and Cellular Longevity (2018), has examined GHK-Cu's modulation of over 4,000 human genes in cell culture models. Additional published work has investigated its interactions with antioxidant enzymes, collagen synthesis pathways, and the ubiquitin-proteasome system in vitro.",
      },
      {
        heading: "Research Applications",
        content:
          "In laboratory settings, GHK-Cu is used as a reference material across several research disciplines. All applications listed represent in vitro or preclinical contexts only.",
        list: [
          "Gene expression modulation studies (microarray, RNA-seq)",
          "Copper-binding peptide chemistry and coordination studies",
          "Antioxidant pathway research (SOD, catalase interactions)",
          "Extracellular matrix and collagen synthesis models",
          "Wound-healing cell migration assays (in vitro scratch assays)",
        ],
      },
      {
        heading: "Purity and Quality Standards",
        content:
          "Research-grade GHK-Cu should meet ≥99% purity by HPLC analysis. Because it is a metal complex, identity confirmation should include both peptide sequence verification and copper content analysis. Vertex Research Labs provides independent third-party COA documentation with every GHK-Cu batch, confirming purity, identity, and copper coordination.",
      },
      {
        heading: "Disclaimer",
        content:
          "GHK-Cu reference materials from Vertex Research Labs are supplied exclusively for laboratory research and analytical purposes. This material is not intended for human or veterinary use. Nothing in this guide constitutes medical advice or a health claim.",
      },
    ],
    faqs: [
      {
        question: "What is the difference between GHK and GHK-Cu?",
        answer:
          "GHK is the free tripeptide (Glycyl-L-Histidyl-L-Lysine). GHK-Cu is the copper(II) complex of GHK. The copper-complexed form is the primary subject of biological research as the copper coordination is central to its documented activities in cell culture studies.",
      },
      {
        question: "How many genes has GHK-Cu been studied in relation to?",
        answer:
          "Microarray and RNA-seq studies in cell culture have examined GHK-Cu's influence on over 4,000 human genes, according to publications by Pickart and colleagues. These are in vitro findings and do not represent clinical outcomes.",
      },
      {
        question: "Is GHK-Cu naturally occurring?",
        answer:
          "Yes. GHK-Cu occurs naturally in human plasma (at approximately 200 ng/mL in young adults, declining with age), as well as in saliva and urine. The synthetic research form is produced to provide consistent, high-purity reference material for laboratory studies.",
      },
      {
        question: "What form does research-grade GHK-Cu ship in?",
        answer:
          "GHK-Cu is supplied as a lyophilized powder in sealed research vials. It is available in 50mg and 100mg formats from Vertex Research Labs.",
      },
    ],
    relatedProducts: ["ghk-cu", "ghk-cu-100", "epithalon", "bpc-157"],
    relatedSlugs: [
      "epithalon-research-overview",
      "research-grade-peptide-purity-standards",
      "how-to-read-peptide-coa",
    ],
  },

  {
    slug: "retatrutide-triple-agonist-research",
    title: "Retatrutide: The Triple Agonist Peptide Researchers Are Watching",
    metaTitle: "Retatrutide Research Overview: GLP-1/GIP/Glucagon Triple Agonist | Vertex Research Labs",
    metaDescription:
      "Research overview of Retatrutide (LY3437943), the GLP-1, GIP, and glucagon triple receptor agonist peptide. Covers structure, Phase 2 trial data, and comparisons with Semaglutide and Tirzepatide.",
    keywords: [
      "Retatrutide research",
      "Retatrutide LY3437943",
      "triple agonist peptide research",
      "GLP-1 GIP glucagon agonist",
      "Retatrutide vs Semaglutide",
      "Retatrutide vs Tirzepatide",
      "Retatrutide Phase 2 trial",
      "GLP-1 peptide research 2024 2025",
      "incretin peptide research",
      "trending peptide research",
    ],
    publishedDate: "2025-02-01",
    modifiedDate: "2025-04-01",
    category: "Research Overview",
    readTime: 8,
    excerpt:
      "Retatrutide (LY3437943) is a synthetic peptide that simultaneously agonizes GLP-1, GIP, and glucagon receptors. Phase 2 trial data published in the New England Journal of Medicine has made it one of the most discussed peptides in metabolic research. This overview covers its structure, receptor pharmacology, and published clinical data.",
    sections: [
      {
        heading: "What Is Retatrutide?",
        content:
          "Retatrutide (INN: retatrutide; Eli Lilly code: LY3437943) is a synthetic acylated peptide designed as a triple agonist at three key metabolic hormone receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This triple-receptor pharmacology distinguishes it structurally from all currently approved GLP-1 class drugs and makes it a significant research subject in metabolic science.",
      },
      {
        heading: "Receptor Pharmacology",
        content:
          "Understanding Retatrutide's receptor targets requires context on the incretin hormone system. GLP-1R and GIPR are both incretin receptors involved in insulin secretion regulation, while GCGR mediates glucagon signaling. Retatrutide's triple agonism creates a distinct pharmacological profile that researchers are using to study the interaction between these three receptor pathways in metabolic regulation.",
        list: [
          "GLP-1R (Glucagon-like Peptide-1 Receptor) — incretin signaling",
          "GIPR (Glucose-dependent Insulinotropic Polypeptide Receptor) — incretin signaling",
          "GCGR (Glucagon Receptor) — counterregulatory hormone signaling",
        ],
      },
      {
        heading: "Phase 2 Clinical Trial Data",
        content:
          "In June 2023, the New England Journal of Medicine published Phase 2 trial results for Retatrutide (Jastreboff AM et al., DOI: 10.1056/NEJMoa2301972). The trial enrolled 338 participants with obesity and examined multiple dose levels over 48 weeks. The published data represents a clinical research finding and does not constitute a treatment claim. Retatrutide remains an investigational compound with no approved indication as of 2025.",
      },
      {
        heading: "Structural Comparison: Retatrutide vs. Semaglutide vs. Tirzepatide",
        content:
          "For researchers studying GLP-1 class peptides, the structural and pharmacological distinctions between these compounds are important reference points.",
        list: [
          "Semaglutide (Ozempic/Wegovy): GLP-1R mono-agonist, C18 fatty diacid acylation, ~34 amino acids",
          "Tirzepatide (Mounjaro/Zepbound): GLP-1R/GIPR dual agonist, C20 fatty diacid acylation, 39 amino acids",
          "Retatrutide (LY3437943): GLP-1R/GIPR/GCGR triple agonist, C20 fatty diacid acylation, ~39 amino acids",
        ],
      },
      {
        heading: "Research Grade Retatrutide Specifications",
        content:
          "As an investigational peptide, research-grade Retatrutide requires rigorous purity verification. Vertex Research Labs supplies Retatrutide at ≥99% purity as independently verified by HPLC, with mass spectrometry identity confirmation and batch-specific COA documentation. It is available in 10mg vials for laboratory use.",
      },
      {
        heading: "Regulatory Status and Disclaimer",
        content:
          "Retatrutide is an investigational compound. As of 2025 it has not received FDA approval or approval from any other regulatory authority for any indication. All Retatrutide reference materials from Vertex Research Labs are supplied exclusively for laboratory research use. This overview is for scientific reference only and does not constitute medical advice or a health claim of any kind.",
      },
    ],
    faqs: [
      {
        question: "What makes Retatrutide different from Semaglutide?",
        answer:
          "Semaglutide is a GLP-1 receptor mono-agonist. Retatrutide targets three receptors simultaneously: GLP-1R, GIPR, and GCGR. This triple-agonism creates a distinct pharmacological profile that is the primary subject of current research interest.",
      },
      {
        question: "Is Retatrutide FDA-approved?",
        answer:
          "No. As of 2025, Retatrutide (LY3437943) is an investigational compound that has not received FDA approval for any indication. It is available only as a research reference material.",
      },
      {
        question: "Where was the Retatrutide Phase 2 trial published?",
        answer:
          "The Phase 2 trial data was published in the New England Journal of Medicine in June 2023 (Jastreboff AM et al., NEJM 2023;389:514-526, DOI: 10.1056/NEJMoa2301972).",
      },
      {
        question: "What purity is research-grade Retatrutide?",
        answer:
          "Research-grade Retatrutide from Vertex Research Labs is independently verified at ≥99% purity by HPLC with a batch-specific Certificate of Analysis.",
      },
      {
        question: "Can I compare Retatrutide to Tirzepatide in my research?",
        answer:
          "Yes — as distinct reference materials, both are available for comparative receptor pharmacology research. Tirzepatide (dual GLP-1R/GIPR agonist) and Retatrutide (triple GLP-1R/GIPR/GCGR agonist) represent useful structural and pharmacological comparators in incretin research.",
      },
    ],
    relatedProducts: ["retatrutide", "tesamorelin", "cjc-ipa-blend"],
    relatedSlugs: [
      "glp1-peptides-research-overview",
      "research-grade-peptide-purity-standards",
      "how-to-read-peptide-coa",
    ],
  },
];
